Are there generic versions of Capmatinib?

Capmatinib (Capmatinib) is a targeted therapy drug mainly used to treat MET primary tyrosine kinase overexpression ( Patients with advanced or metastatic non-small cell lung cancer (NSCLC) with METex14skipping mutations or METincreased).

There are generic versions of capmatinib, mainly Laotian generic versions. Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

METex14skipping mutation is a relatively rare type of mutation in non-small cell lung cancer. The patient's MET gene has mutations that lead to its abnormal activation. As a targeted drug, capmatinib can inhibit the activity of MET kinase, thereby blocking the MET signaling pathway and inhibiting the growth and spread of tumor cells. It has a unique efficacy in the treatment of METex14 skipping mutant NSCLC patients.

In addition toMETex14skipping mutations, the increase in the MET gene is also an important abnormality in non-small cell lung cancer. In METproliferativeNSCLC patients, overexpression of MET kinase leads to abnormal proliferation and metastasis of tumor cells. Capmatinib, as a targeted therapeutic drug against METkinase, also has certain efficacy in the treatment of METproliferated NSCLC patients.

In addition to the above approved indications, capmatinib may also be used in other clinical trials and studies. Scientists and medical researchers may further explore capmatinib's potential efficacy in other types of cancer, or in combination with other drugs.